Huadong and Insilico Partner to Discover Novel Oncology Candidates

Huadong Medicine entered a co-development partnership with Insilico Medicine, a Hong Kong AI drug discovery company. The two companies will work together to develop small-molecule therapeutics in oncology. Huadong will use its drug discovery and screening platform, while Insilico will contribute its end-to-end AI-driven drug discovery platform, including its small molecule generation platform, Chemistry42, to design and screen for potential first-in-class drug molecules with improved druggability. The teams plan to interfere with protein-protein interactions to hit undruggable targets that regulate tumor growth. More details.... Stock Symbol: (SHZ: 000963) Share this with colleagues: // //